Invitrocue Hong Kong

Invitrocue Limited is an innovative life sciences company that specialises in developing in vitro and in vivo models that improve the efficacy and safety evaluation of new drugs for biotechnology, pharmaceutical, and consumer healthcare companies. Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions. Our expertise in developing predictive preclinical models can help to reduce the time and cost of product development and minimize the risks of downstream testing. By enabling assessments of the best ways for drugs to be developed, Invitrocue creates better, faster and more affordable disease treatments, that work towards the company’s goal of creating a healthier society by providing patients with the best possible care. To learn more please visit: https://www.invitrocue.com